222 related articles for article (PubMed ID: 16317287)
21. Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.
Mahal K; Biersack B; Caysa H; Schobert R; Mueller T
Invest New Drugs; 2015 Jun; 33(3):541-54. PubMed ID: 25678082
[TBL] [Abstract][Full Text] [Related]
22. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Galbraith SM; Chaplin DJ; Lee F; Stratford MR; Locke RJ; Vojnovic B; Tozer GM
Anticancer Res; 2001; 21(1A):93-102. PubMed ID: 11299795
[TBL] [Abstract][Full Text] [Related]
23. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.
Luo Y; Hradil VP; Frost DJ; Rosenberg SH; Gordon GB; Morgan SJ; Gagne GD; Cox BF; Tahir SK; Fox GB
Anticancer Drugs; 2009 Jul; 20(6):483-92. PubMed ID: 19398903
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.
Arthuis M; Pontikis R; Chabot GG; Seguin J; Quentin L; Bourg S; Morin-Allory L; Florent JC
ChemMedChem; 2011 Sep; 6(9):1693-705. PubMed ID: 21732536
[TBL] [Abstract][Full Text] [Related]
25. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
Moon CH; Lee SJ; Lee HY; Dung le TK; Cho WJ; Cha H; Park JW; Min YJ
Invest New Drugs; 2014 Jun; 32(3):400-11. PubMed ID: 24202729
[TBL] [Abstract][Full Text] [Related]
26. 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.
Lee HY; Chang JY; Nien CY; Kuo CC; Shih KH; Wu CH; Chang CY; Lai WY; Liou JP
J Med Chem; 2011 Dec; 54(24):8517-25. PubMed ID: 22060033
[TBL] [Abstract][Full Text] [Related]
27. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.
Quan H; Xu Y; Lou L
Int J Cancer; 2008 Apr; 122(8):1730-7. PubMed ID: 18074350
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of sphingolipids in MRP1 overexpressing HT29 cells.
Kok JW; Veldman RJ; Klappe K; Koning H; Filipeanu CM; Müller M
Int J Cancer; 2000 Jul; 87(2):172-8. PubMed ID: 10861470
[TBL] [Abstract][Full Text] [Related]
29. Natural product derivative Bis(4-fluorobenzyl)trisulfide inhibits tumor growth by modification of beta-tubulin at Cys 12 and suppression of microtubule dynamics.
Xu W; Xi B; Wu J; An H; Zhu J; Abassi Y; Feinstein SC; Gaylord M; Geng B; Yan H; Fan W; Sui M; Wang X; Xu X
Mol Cancer Ther; 2009 Dec; 8(12):3318-30. PubMed ID: 19996274
[TBL] [Abstract][Full Text] [Related]
30. Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.
Belzacq-Casagrande AS; Bachelot F; De Oliveira C; Coutadeur S; Maurier-Mahé F; Throo E; Chauvignac C; Pognante L; Petibon A; Taverne T; Beausoleil E; Leblond B; Pando MP; Désiré L
Invest New Drugs; 2013 Apr; 31(2):304-19. PubMed ID: 22878926
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Holwell SE; Cooper PA; Thompson MJ; Pettit GR; Lippert LW; Martin SW; Bibby MC
Anticancer Res; 2002; 22(6C):3933-40. PubMed ID: 12553015
[TBL] [Abstract][Full Text] [Related]
32. Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models.
Reipsch F; Biersack B; Lucas H; Schobert R; Mueller T
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884888
[TBL] [Abstract][Full Text] [Related]
33. Vascular disrupting activity of combretastatin analogues.
Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and SAR requirements of adamantane-colchicine conjugates with both microtubule depolymerizing and tubulin clustering activities.
Zefirova ON; Nurieva EV; Shishov DV; Baskin II; Fuchs F; Lemcke H; Schröder F; Weiss DG; Zefirov NS; Kuznetsov SA
Bioorg Med Chem; 2011 Sep; 19(18):5529-38. PubMed ID: 21873068
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent.
Rickardson L; Kutvonen E; Orasniemi S; Högberg M; Kallio MJ; Rehnmark S
Drug Des Devel Ther; 2017; 11():1335-1351. PubMed ID: 28496304
[TBL] [Abstract][Full Text] [Related]
36. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
Galmarini CM; Martin M; Bouchet BP; Guillen-Navarro MJ; Martínez-Diez M; Martinez-Leal JF; Akhmanova A; Aviles P
BMC Cancer; 2018 Feb; 18(1):164. PubMed ID: 29415678
[TBL] [Abstract][Full Text] [Related]
37. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
Micheletti G; Poli M; Borsotti P; Martinelli M; Imberti B; Taraboletti G; Giavazzi R
Cancer Res; 2003 Apr; 63(7):1534-7. PubMed ID: 12670901
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel vinyl sulfone derivatives as anti-tumor agents with microtubule polymerization inhibitory and vascular disrupting activities.
Li W; Yin Y; Yao H; Shuai W; Sun H; Xu S; Liu J; Yao H; Zhu Z; Xu J
Eur J Med Chem; 2018 Sep; 157():1068-1080. PubMed ID: 30176537
[TBL] [Abstract][Full Text] [Related]
39. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
[TBL] [Abstract][Full Text] [Related]
40. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity.
Bacher G; Nickel B; Emig P; Vanhoefer U; Seeber S; Shandra A; Klenner T; Beckers T
Cancer Res; 2001 Jan; 61(1):392-9. PubMed ID: 11196193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
